Admilparant Meets Phase 3 Endpoint in IPF Trial

Admilparant 60 mg met the primary endpoint in the Phase 3 ALOFT-IPF trial, significantly improving forced vital capacity versus placebo at 52 weeks in patients with idiopathic pulmonary fibrosis, according to topline data reported by HCPLive and The American Journal of Managed Care.

What Happened

The ALOFT-IPF trial tested two doses of admilparant against placebo. The 60 mg dose achieved statistical significance on the primary endpoint of change in forced vital capacity at 52 weeks, according to HCPLive. The 120 mg dose missed statistical significance, HCPLive reported.

Forced vital capacity measures the maximum amount of air a person can exhale after a deep breath. It is a standard measure of lung function in IPF.

Why It Matters

Idiopathic pulmonary fibrosis is a progressive and fatal lung disease. Treatment options remain limited. The trial results suggest admilparant at the 60 mg dose may offer a new approach to slowing lung function decline in this patient population.

The finding that the higher dose did not achieve statistical significance may inform dosing decisions if the drug advances toward regulatory review.

What It Means for People in the Industry

If admilparant proceeds to regulatory submission and approval, development and commercialisation activities could create demand for clinical, regulatory and manufacturing expertise in respiratory therapeutics. Watch for announcements about regulatory filings and partnership or expansion plans.

Read more pharma and biotech news.

Sources

• Admilparant Phase 3 ALOFT-IPF Trial Meets Primary End Point in IPF, The American Journal of Managed Care
• ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point, HCPLive